The latest clinical research protocol of carrelizumab and apatinib mesylate combined with vascular interventional treatment of unresectable solid tumors will be featured in the 2021 ESMO poster

Shanghai, October 18, 2021/PRNewswire/ - Recently, the innovative drugs carrelizumab and apatinib mesylate independently developed by Jiangsu Hengrui Pharmaceutical Co.

2021 European Society for Medical Oncology (ESMO) Annual Conference Poster Presentation[1]

Interventional therapy (TACE) plays an important role in the treatment of malignant tumors

Anti-angiogenic drugs combined with immunotherapy can reshape the tumor immunosuppressive microenvironment

According to Professor Gao Feng, the principal investigator of the study and the chief physician of the Third Department of Oncology, Peking Dahuang Group General Hospital, “On the one hand, immunotherapy represented by vascular interventional therapy combined with immune checkpoint inhibitors has a synergistic effect in activating immune function

This study plans to enroll 30 patients with unresectable solid tumors

Carrelizumab is a humanized anti-PD-1 monoclonal antibody.

Expert profile:

Gao Feng, Chief Physician

Director of the Third Department of Oncology, Peking Dahuang Group General Hospital

He graduated from the Department of Clinical Medicine in 1991 and has been engaged in comprehensive treatment of malignant tumors for nearly 30 years

Standing Member of the Radiotherapy Committee of the Chinese Society of Geriatric Oncology

Director of Heilongjiang Medical Association, Member of Heilongjiang Medical Association Oncology Committee, Standing Committee of Heilongjiang Medical Association Provincial Lung Cancer and Tumor Palliative Care Professional Committee

Director of Heilongjiang Medical Association

Vice Chairman of Heilongjiang Provincial Medical Care International Exchange Promotion Association Tumor Precision Medicine and Radiotherapy Professional Committee

Standing member of the Respiratory Medicine Professional Committee of Heilongjiang Research Hospital Association

Member of the 10th, 11th and 12th CPPCC Heilongjiang Province

references:

[1] Feng G, Lili L, Lei S, et al.

[2] Zhao S, Ren S, Jiang T, et al.

Source: Jiangsu Hengrui Pharmaceutical Co.